Lidocaine hydrochloride veterinary-grade API, also identified as lignocaine hydrochloride or Xylocaine, is the amide-type local anesthetic supplied as the hydrochloride monohydrate (CAS 6108-05-0; molecular formula C₁₄H₂₂N₂O·HCl·H₂O; molecular weight 288.82 g/mol). The anhydrous hydrochloride form carries CAS 73-78-9. No discrete model suffix exists in compendial nomenclature; the API is released under the pharmacopeial monograph name and a manufacturer lot-specific certificate of analysis. The material appears as a white or almost white crystalline powder, freely soluble in water and soluble in ethanol. In aqueous solution at 1 in 20 dilution, the pH is typically controlled within 4.0–5.5 by compendial monograph. The salt form is directly dispersible in aqueous pharmaceutical processes, whereas the poorly water-soluble base is typically reserved for topical or non-aqueous formulations. For tablet, capsule, powder, granule, premix, and parenteral solution routes, the monohydrate water content and particle-size distribution are the two release properties most likely to affect downstream process capability.

Process selection depends on the dosage form. Injectable solutions require dissolution in water for injection to a final concentration commonly expressed as lidocaine hydrochloride 20 mg/mL or 10 mg/mL for veterinary use; tablets, capsules, and granules require dry blending, wet granulation, or roller compaction. Powder and premix forms are usually manufactured by geometric dilution from a milled API into a feed-grade carrier. In all cases, pH excursions above 7.0 shift the equilibrium toward the free base and can produce an oily precipitate that is difficult to redisperse. This boundary is relevant in multi-drug admixtures and in hard water used for oral liquid compounding. Compendial compliance is anchored to USP-NF and Ph. Eur. monographs for lidocaine hydrochloride, with residual solvent testing under USP <467> and water determination under USP <921> Method Ia.

Compendial Specification Boundaries for Veterinary-Grade Lidocaine Hydrochloride

Release testing should be performed against the current USP-NF and Ph. Eur. monographs for lidocaine hydrochloride. Identity confirmation is by infrared absorption spectrophotometry consistent with the reference spectrum and by the characteristic reaction of chloride ions. Water content is determined by Karl Fischer titration using USP <921> Method Ia; the monohydrate specification is commonly 5.5%–7.0%, which corresponds to approximately one mole of water per mole of lidocaine hydrochloride. pH of a 1 in 20 aqueous solution is measured by USP <791> with a calomel or glass electrode system. Residue on ignition is limited to ≤0.1% under USP <281>. Related substances and assay are commonly performed by HPLC using USP <621>; exact impurity thresholds are defined in the monograph, and supplier specifications may set an individual impurity reporting threshold of 0.10%.

Table 1 lists the typical release parameters for the veterinary-grade monohydrate. Analytical values should be read against the manufacturer certificate of analysis because some monographs allow anhydrous and monohydrate forms with different water limits. Drying above 105°C is not recommended for routine moisture measurement because it can remove lattice water and produce an anhydrous form; Karl Fischer titration is preferred. The monohydrate should be stored in tightly closed containers at controlled room temperature and protected from light. If bulk material is repeatedly opened in high-humidity environments, water uptake may exceed specification and require reprocessing or rejection.

Table 1. Typical release parameters for lidocaine hydrochloride monohydrate.

For dry powder processes, the monohydrate is milled or co-milled with microcrystalline cellulose, lactose monohydrate, or anhydrous dibasic calcium phosphate to reduce agglomeration and improve flow. Direct compression of lidocaine hydrochloride as a single component is limited by its particle-size distribution and flow properties; published data for exact Carr index values of this veterinary-grade API are limited. Production-scale tableting lines typically run at press speeds from 30 to 80 rpm when the formulation contains at least 20% direct-compressible filler. Lubricant addition should not exceed 1.0% magnesium stearate by weight, and extended blending beyond 5 min is avoided because shear-induced coating can reduce tablet hardness and dissolution rate. Capsule filling on dosator machines may require pre-compression or slugging to increase bulk density; tamping-pin fillers usually tolerate lower-density powders better. Particle-size distribution may be monitored by USP <786> analytical sieving.

Wet granulation is used for higher load or for granule-based veterinary formulations. A high-shear mixer with an impeller tip speed below 5 m/s and an L/D ratio appropriate for the bowl capacity is common for laboratory and production-scale batches. Granulation end point is better controlled by power consumption or torque rather than fixed time because lidocaine hydrochloride is water-soluble and can overwet rapidly. The granule moisture after drying should be returned to 5.5%–7.0% if monohydrate stability is required; dried granules above 7.0% water content may be sticky and may cause picking or sticking on tablet punches. Roller compaction can be used for moisture-sensitive combination products, but ribbed rolls set to a gap of 1.0–2.0 mm and a hydraulic pressure appropriate for the formulation should be evaluated case by case. For continuous wet granulation, twin-screw extruders with an L/D ratio of 20:1 to 40:1 have been evaluated, but published data for this veterinary-grade API in continuous granulation are limited.

What Limits Solution and Injectable Throughput at the Fill Line?

Aqueous injectable solutions are prepared by dissolving lidocaine hydrochloride in water for injection. Because the hydrochloride is freely soluble in water, the dissolution step is not rate-limiting in production; the critical constraints are pH, microbial control, filter compatibility, and terminal sterilization. The target pH is usually adjusted with dilute hydrochloric acid or sodium hydroxide to 4.0–5.5. Alkaline adjustment above pH 7.0 can precipitate free base, and the precipitate may not redissolve completely upon acidification if it has coalesced. The compounding vessel is usually a jacketed stainless-steel tank with bottom-mounted magnetic drive or mechanical mixer; dissolved oxygen is minimized by nitrogen overlay if the solution will be held for more than 8 h before filtration. Bulk solutions are filtered through 0.22 µm sterilizing-grade membrane filters, commonly PVDF or polyethersulfone, and filled into pre-sterilized containers. Filter compatibility testing should be performed because lidocaine hydrochloride can interact with certain filter materials at low pH.

Terminal sterilization of sealed vials is commonly performed at 121°C for 15 min by saturated steam autoclave, although the exact cycle is determined by container size and load validation. Sterility release is governed by USP <71>, bacterial endotoxin by USP <85>, and particulate matter by USP <788>. For veterinary parenteral products, USP <1> injectable general chapter and FDA 21 CFR 211 current good manufacturing practice apply to finished pharmaceuticals. Physical stability during the filling campaign requires that the solution remain below 40°C; prolonged heating may lead to minor hydrolytic degradation. The main operational boundary is incompatibility with bicarbonate-containing diluents, aminophylline, or other alkaline admixtures due to free base precipitation. Solutions should not be mixed in the same line with β-lactam antibiotics without line flushing, because pH and solvent changes can cause particulate formation.

For powders, granules, and veterinary premixes, the API is usually first screened or milled to a defined particle-size distribution and then diluted by geometric addition to a feed-grade carrier such as lactose monohydrate, dextrose, or corn cob. The blend uniformity requirement is validated by sampling at the beginning, middle, and end of a ribbon blender or V-blender using USP <905> for dosage uniformity or a validated blend uniformity method. Blend times are generally 10–20 min after the API premix has been passed through a 20-mesh screen to break soft agglomerates. High-shear mixing is not necessary for simple premixes and may generate electrostatic adhesion to stainless steel surfaces if humidity falls below 30% relative humidity. Granule production for oral administration frequently uses fluid-bed granulation with inlet air temperature set between 50°C and 70°C; higher temperatures can cause surface drying of the granule while the core remains wet, producing friable granules and variable assay. Loss on drying after fluid-bed granulation should be checked against the monohydrate water specification; if the granule formulation is intended for sachets or reconstitution, an overage of not more than 1.0% may be needed to cover filling losses, but the overage must be justified by batch data.

Premixes intended for incorporation into medicated feed are subject to FDA 21 CFR 225 and 226 for Type A medicated articles when applicable; the API should be mixed with a suitable carrier to achieve a target concentration that is safe for the species and route. Cross-contamination control requires dedicated or validated cleaning procedures because lidocaine hydrochloride is pharmacologically active at low doses in small animals. Analytical confirmation is by HPLC with UV detection, often at 254 nm or by a validated method under USP <1225>. The operational boundary for powder blending is moisture ingress; if environmental relative humidity exceeds 60%, the monohydrate may become sticky and blend uniformity may deteriorate. Published data for this specific veterinary-grade API in low-moisture premix carriers are limited, so scale-up should be confirmed by triplicate process qualification batches.

Under ambient storage, the API monohydrate is normally assigned a manufacturer retest date; 24-month intervals are common for similar monohydrate APIs stored in sealed containers at 15°C–25°C. Accelerated stability studies are conducted at 40°C/75% relative humidity per ICH Q1A guidelines; however, published data for this veterinary-grade API at these exact conditions are limited. The monohydrate should not be stored in open containers at relative humidity above 60% because the powder may cake. Light protection is recommended because lidocaine hydrochloride solutions can undergo yellowing under prolonged UV exposure. For sterile injectable solutions, in-use stability after container opening is validated with preservative efficacy testing under USP <51> if multiple-dose vials contain a preservative; unpreserved single-dose containers should not be reused. For oral solution and premix finished products, microbial limits are tested under USP <61> and USP <62>. Packaging components should be inert: type I glass vials with halobutyl rubber stoppers for injections, and polyethylene-lined fiber drums for bulk API. Incompatibilities include strong oxidizing agents and prolonged contact with copper or iron, which may catalyze oxidative degradation in aqueous solutions at low pH.

When Local Anesthetic Potency and Duration Are Compared Across Salts

Lidocaine hydrochloride is an amide-type local anesthetic; the hydrochloride salt differentiates it from lidocaine base and from ester-type agents such as procaine hydrochloride. Compared with bupivacaine hydrochloride, lidocaine hydrochloride has a shorter duration of action and a lower reported plasma protein binding. Compared with procaine hydrochloride, lidocaine is metabolized primarily by hepatic N-dealkylation, whereas procaine is rapidly hydrolyzed by plasma pseudocholinesterase. This metabolic difference affects selection in animals with hepatic impairment. The ionization constant (pKa) of lidocaine is reported in the range 7.7–7.9, close to mepivacaine and lower than procaine or bupivacaine; the lower pKa means a greater proportion of non-ionized base diffuses across the nerve membrane at tissue pH, contributing to faster onset. The log P of the unionized base is approximately 2.4, indicating intermediate lipophilicity. In veterinary formulations, the hydrochloride salt is preferred for aqueous injections, oral solutions, and wet granulation because it dissolves easily; the base is used in topical creams, gels, and wax-based preparations.

Table 2 provides a comparative matrix for common injectable local anesthetics used in veterinary medicine. Values are representative literature ranges and should not be used as species-specific dose adjustments. The onset and duration values are for infiltration anesthesia without vasoconstrictor; epinephrine or other vasoconstrictors can prolong duration and reduce peak plasma concentrations.

Table 2. Comparative matrix for common injectable local anesthetic salts.